Introduction
MULTIPLE MYELOMA (MM), MYELOMA
Novel therapeutics have significantly improved response rates as well as the depth of response in patients with multiple myeloma (MM) [The minimally invasive technology mass spectrometry (MS), which is amenable to automation, is emerging as a promising approach for detecting and monitoring monoclonal proteins in the peripheral blood (PB) [To provide further evidence of the clinical value of MS and to explore whether it provides independent prognostic information, we have retrospectively tracked treatment response by serum MS in patients who had been enrolled in the German-speaking Myeloma Multicenter Group (GMMG) multicenter phase III GMMG-MM5 trial (EudraCT No. 2010-019173-16). The primary endpoint of the trial investigated continuation versus omission of lenalidomide maintenance for patients achieving a CR [